stockportfolio.pro
Stocks / BDX vs TEVA
BDX vs TEVA
Becton, Dickinson and Company and Teva Pharmaceutical Industries Limited side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Becton, Dickinson and Company (BDX) | Teva Pharmaceutical Industries Limited (TEVA) | |
|---|---|---|
| Market cap | $41.9B | $40.1B |
| Revenue (latest FY) | $21.84B | $17.26B |
| Net income (latest FY) | $1.68B | $1.41B |
| Revenue growth (5y CAGR) | 6.3% | 0.7% |
| Net margin | 7.7% | 8.2% |
| Return on equity | 6.6% | 17.8% |
| P/E ratio | 26.5 | 25.7 |
| Dividend yield | 2.8% | — |
| Profitable years (of last 10) | 10 | 3 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open BDX — free Open TEVA — freeFrequently asked questions
Which is bigger, BDX or TEVA?
Becton, Dickinson and Company is larger by market capitalization — $41.9B versus $40.1B.
Which grows faster, BDX or TEVA?
Over the last five fiscal years, Becton, Dickinson and Company grew revenue faster — 6.3%/yr versus 0.7%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.